Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 306

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Risks of Less Common Cancers in Proven Mutation Carriers With Lynch Syndrome

Open access
Engel, Christoph, Loeffler, Markus, Steinke, Verena, Rahner, Nils, Holinski-Feder, Elke, Dietmaier, Wolfgang, Schackert, Hans K., Goergens, Heike, von Knebel Doeberitz, Magnus, Goecke, Timm O., Schmiegel, Wolff, Buettner, Reinhard, Moeslein, Gabriela, Letteboer, Tom G.W., García, Encarna Gómez, Hes, Frederik J., Hoogerbrugge, Nicoline, Menko, Fred H., van Os, Theo A.M., Sijmons, Rolf H., Wagner, Anja, Kluijt, Irma, Propping, Peter, Vasen, Hans F.A.·2012·Journal of Clinical Oncology

Abstract

Purpose: Patients with Lynch syndrome are at high risk for colon and endometrial cancer, but also at an elevated risk for other less common cancers. The purpose of this retrospective cohort study was to provide risk estimates for these less common cancers in proven carriers of pathogenic mutations in the mismatch repair (MMR) genes MLH1, MSH2, and MSH6. Patients and Methods: Data were pooled from the German and Dutch national Lynch syndrome registries. Seven different cancer types were analyzed: stomach, small bowel, urinary bladder, other urothelial, breast, ovarian, and prostate cancer. Age-, sex- and MMR gene–specific cumulative risks (CRs) were calculated using the Kaplan-Meier method. Sex-specific incidence rates were compared with general population incidence rates by calculating standardized incidence ratios (SIRs). Multivariate Cox regression analysis was used to estimate the impact of sex and mutated gene on cancer risk. Results: The cohort comprised 2,118 MMR gene mutation carriers (MLH1, n = 806; MSH2, n = 1,004; MSH6, n = 308). All cancers were significantly more frequent than in the general population. The highest risks were found for male small bowel cancer (SIR, 251; 95% CI, 177 to 346; CR at 70 years, 12.0; 95% CI, 5.7 to 18.2). Breast cancer showed an SIR of 1.9 (95% CI, 1.4 to 2.4) and a CR of 14.4 (95% CI, 9.5 to 19.3). MSH2 mutation carriers had a considerably higher risk of developing urothelial cancer than MLH1 or MSH6 carriers. Conclusion: The sex- and gene-specific differences of less common cancer risks should be taken into account in cancer surveillance and prevention programs for patients with Lynch syndrome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2012.43.2278

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 306

Metadata

Authors
Engel, C., Loeffler, M., Steinke, V., Rahner, N., Holinski-Feder, E., Dietmaier, W., Schackert, H. K., Goergens, H., von Knebel Doeberitz, M., Goecke, T. O., Schmiegel, W., Buettner, R., Moeslein, G., Letteboer, T. G. W., García, E. G., Hes, F. J., Hoogerbrugge, N., Menko, F. H., van Os, T. A. M., Sijmons, R. H., Wagner, A., Kluijt, I., Propping, P., & Vasen, H. F. A.
Venue
Journal of Clinical Oncology
Published
2012-12-10
Volume
30
Issue
35
Pages
4409-4415
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2129567712
Cited by
306
References
28
FWCI
14.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risks of Less Common Cancers in Proven Mutation Carriers With Lynch Syndrome. https://app.cochat.ai/papers/10.1200/jco.2012.43.2278
The paper
Engel, C., Loeffler, M., Steinke, V., Rahner, N., Holinski-Feder, E., Dietmaier, W., Schackert, H. K., Goergens, H., von Knebel Doeberitz, M., Goecke, T. O., Schmiegel, W., Buettner, R., Moeslein, G., Letteboer, T. G. W., García, E. G., Hes, F. J., Hoogerbrugge, N., Menko, F. H., van Os, T. A. M., . . . Vasen, H. F. A. (2012). Risks of Less Common Cancers in Proven Mutation Carriers With Lynch Syndrome. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.43.2278

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.